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Haptoglobin: a review of the major allele frequencies
worldwide and their association with diseases
KYMBERLEY CARTER*, MARK WORWOOD
HAPTOGLOBIN STRUCTURE AND FUNCTION
Polonovski and Jayle (1940) first described a protein
with haemoglobin binding properties, which they
later designated ‘haptoglobin’, from the Greek word
haptein – to bind.
Haptoglobin (Hp) is a plasma a2-glycoprotein syn-
thesized primarily by hepatocytes (Putnam, 1975).
Synthesis is stimulated by infection or inflammation
(the acute phase response). After release into the cir-
culation it has a half-life of 2–4 days (Garby & Noyes,
1959). Haptoglobin binds oxygenated, free haemoglo-
bin with a very high affinity of approximately
1 · 10)15 mol/l (Okazaki, Yanagisawa & Nagai, 1997).
Free haemoglobin can be harmful to the body, pro-
moting the accumulation of hydroxyl radicals via the
Fenton reaction (H2O2 + Fe
2+ ﬁ Fe3+ + OH) + OH),
resulting in oxidative tissue damage (Sadrzadeh et al.,
1984). Once irreversibly bound to haptoglobin, free
haemoglobin loses its oxidizing ability (Sadrzadeh
et al., 1984; Gutteridge, 1987). The haptoglobin–
haemoglobin (Hp–Hb) complex is removed from the
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SUMMARY
Haptoglobin (Hp) is a plasma a2-glycoprotein which binds free
haemoglobin, thus preventing oxidative damage. The complex is
rapidly removed from the circulation by a specific receptor (CD163)
found on macrophages. Three major subtypes, Hp1-1, Hp2-1 and
Hp2-2 are the product of two closely related genes HP1 and HP2. The
frequency of the HP1 and HP2 genes varies worldwide depending on
racial origin: the HP1frequency varying from about 0.07 in parts of
India to over 0.7 in parts of West Africa and South America. Both HP1
and HP2 have been linked to susceptibility to various diseases. Such
associations may be explained by functional differences between the
subtypes in the binding of Hb and its rate of clearance from the plasma.
However, there are also corresponding negative reports for disease
associations. The conflicting evidence on disease association and the
lack of association between disease and particular populations, despite
the wide range of HP1 and HP2 gene frequencies across the world, may
indicate that any associations are marginal.
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circulation by binding to a receptor (CD163) found
on the cell surface of monocytes and macrophages
(Kristiansen et al., 2001). Binding instigates the endo-
cytosis of the Hp–Hb complex into the macrophage.
Here the iron is released by haem oxygenase and
transported back to the bone marrow via plasma
transferrin, for synthesis of new haemoglobin. Hapto-
globin is not recycled and when haptoglobin is com-
pletely saturated with free haemoglobin, levels can
take 5–7 days to recover, because synthesis is not
increased by low haptoglobin levels (Putnam, 1975).
THE HAPTOGLOBIN GENE (HP)
Haptoglobin was first described as polymorphic by
Smithies who used starch gel electrophoresis to separ-
ate the various types (Smithies, 1955) and the exist-
ence of two autosomal genes with incomplete
penetrance was proposed by Smithies and Walker
(1955). These give rise to three major phenotypes in
man (Smithies & Walker, 1956) still commonly
referred to as Hp1-1, Hp2-1 and Hp2-2. They can be
distinguished using starch gel or polyacrylamide gel
electrophoresis according to their different sizes and
band patterns (Hp1-1 ¼ ca 100 kDa; Hp2-1 ¼ 120–
220 kDa; Hp2-2 ¼ 160–500 kDa). Haptoglobin is com-
posed of two a-chains and two identical b-chains. The
a-chains are linked together by a disulphide bond,
and each b-chain is similarly bonded to an a-chain
giving the simple chain formula of (ab)2 for the
monomeric form. Haptoglobin shows a high degree of
homology to the proteins in the chymotrypsinogen
family of serine proteases. The molecular weight of
the Hp1 a-chains is 8900 ± 400, while that for the
Hp2 a-chain is 17 300 ± 1400 (Smithies, Connell &
Dixon, 1962). The b-chain is identical for both types,
with a molecular weight of approximately 40 000
(Cheftel & Moretti, 1966).
The identification of haptoglobin phenotype based
on its molecular size using electrophoresis has led to
the suggestion that the complex patterns of Hp2-1 and
Hp2-2 result from a series of polymers composed of two
kinds of subunits. The product of the HPa1 forms only
a dimer, while the product of HPa2 forms higher
polymers, including polymers with the HPa1 product
(Allison, 1959; Smithies, 1959). The series of Hp2-2
polymers (a3b3, a4b4,…) differ in molecular weight by
an average increment of 54 500 (Fuller et al., 1973).
In the Chimp, Gorilla and Old World monkeys,
there are three genes in the haptoglobin family, HP,
HPR and HPP. The evolution of these genes in primates
is discussed by Maeda and Smithies (1986) and McE-
voy and Maeda (1988). Humans have HP and HPR,
and New World monkeys have only HP. There is no
evidence of multiple band patterns in any species but
man, suggesting that the HPa2 allele arose subsequent
to the separation of the human evolutionary line from
other primates, approximately 6 million years ago.
Although the HPR gene was thought to be expressed
only in primates (Maeda & Smithies, 1986) the hapto-
globin-related protein (Hpr) has been identified in
human serum at 5–10% of Hp levels. This protein
binds Hb with high affinity but the Hpr–Hb complex is
not recognized by the CD163 receptor (Nielsen et al.,
2006). Hpr is a component of trypanosome lytic factor-
1, a subclass of HDL (Smith & Hajduk, 1995).
The HP1 gene consists of five exons that encode a
protein of 347 amino acids with a molecular mass of
38 kDa. The first four exons encode the a-subunit
(a1) consisting of 42 amino acids while the fifth
encodes the b-subunit (Maeda, 1991). The HP1 allele
can be further subdivided into the HP1F and HP1S alle-
les, which differ in their a-chains (see Table 1). This
leads to a difference in electrophoretic mobilities, as
HP1F migrates faster than HP1S – hence the names fast
(F) and slow (S) (Connell, Smithies & Dixon, 1966).
The HP2 gene consists of seven exons encoding a
protein of 406 amino acids with a molecular mass of
45 kDa. The first six exons encode a larger a-subunit
(a2) consisting of 83 amino acids and the seventh
encodes the b-subunit (Maeda, 1991).
Smithies, Connell and Dixon (1962) and Bearn and
Franklin (1958) proposed that HP2 was a partially
duplicated gene formed by a rare non-homologous
crossover event that fused HP1F and HP1S genes (see
later). This was confirmed by sequence analysis which
Table 1. Differences between the HP1F and HP1S
variants of the HP1 allele
HP1F HP1S
Amino acid 47 Valine (GTA) Valine (GTG)
Amino acid 51 Asparagine (AAT) Asparagine (AAC)
Amino acid 52 Aspartic acid Asparagine
Amino acid 53 Lysine Glutamic acid
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indicated a 1.7 kb intragenic duplication that encoded
an additional two exons identical to exons 3 and 4 of
HP1 (Yang et al., 1983). Unequal crossing over
between HP1F and HP1S in a HP1F/HP1S heterozygote
produced an HP2 allele described as HP2FS. Crossing
over between HP2 (HP2FS) and either HP1F or HP1S in
HP2/HP1 heterozygotes produced the HP2FF, HP2SS and
the HP2SF alleles. The product of the latter is indistin-
guishable on electrophoresis from that of HP2FS.
Since the discovery of the three major phenotypes
of haptoglobin, other haptoglobin a- and b-chain have
been identified on electrophoresis (see Table 2). Most
are not commonly screened for since they are rare
and do not constitute a significant source of error in
estimating the major gene frequencies.
IDENTIF ICATION OF HAPTOGLOBIN
PHENOTYPES
Most methods of haptoglobin phenotyping are based
upon electrophoretic separation in a gel medium
according to size. Larger molecules are impeded more
than small molecules in their migration through the
gel. Hp1-1 has a single, fast moving band, whilst Hp2-
1 and Hp2-2 each have multiple bands, which differ
in size and electrophoretic mobility (see Figure 1).
This is because the HP2 product is capable of produ-
cing homopolymers (Hp2-2) and heteropolymers
(Hp2-1) (Bearn & Franklin, 1958; Allison, 1959;
Smithies, 1959). The bands present in Hp2-1 differ
from those of Hp2-2, and the Hp1-1 band can be seen
in the Hp2-1 series (Allison & ap Rees, 1957).
Assessing haptoglobin phenotype population fre-
quencies using electrophoretic techniques is not
always accurate. In many populations, a proportion of
subjects have low or even undetectable haptoglobin
levels due to severe haemolysis. These people are
termed anhaptoglobinaemic (no detectable haptoglo-
bin) or hypohaptoglobinaemic (extremely low levels
of haptoglobin) and are classified as ‘Hp0’ in most
screening studies. The real phenotype of ‘Hp0’ sub-
jects may not be detectable so where a significant pro-
portion of the population are Hp0 the frequencies of
Hp1-1, 2-1 and 2-2 may not be accurate.
PCR-based methods have been developed enabling
the identification of haptoglobin allele types in all
Table 2. Haptoglobin a- and b-chain variants detected by electrophoresis listed in order of discovery. Deletions and other
mutations associated with ahaptoglobinaemia and anhaptoglobinaemia are listed at http://www.hgmd.cf.ac.uk/. There are
population speciﬁc base substitutions at the promoter region (Teye et al., 2006)
Name Reported by Notes
Hp Ca (Carlberg) Galatius-Jensen (1958) An a-chain variant with a mixture of Hp2-2 and Hp2-1 bands
Hp2-1M (Modified) Connell and Smithies (1959) An a-chain variant encoded by a Hpa2M allele (Giblett &
Steinberg, 1960). Maeda found 3 other promoter sequences
to explain the variability of the modified phenotype
(Maeda, 1991)
Hp2-1 Haw Giblett, Hickman and
Smithies (1964)
An a-chain variant whose pattern shows a high proportion
of a1-chains compared with a2
Hp Johnson Oliviero et al., (1985) A variant with a larger a-chain due to a threefold tandem
repeat of a 1.7 kbp DNA segment
Hp1-P & Hp2-P Robson et al. (1964) A b-chain variant identified in the presence of haemoglobin
by the faster migration of bands, some of which were doubled
Hp1-H & Hp2-H Robson et al. (1964) A b-chain variant resembling Hp2-1 and Hp2-2 but with an
extra band in the presence of haemoglobin
Hp Mb (Marburg) Cleve and Deicher (1965) A b-chain variant resulting from a mutational event causing
one or two mutant b-chains
Hp2-1D (Dashing) Renwick and Marshall
(1966)
An a-chain variant from the Hpa1D allele, only distinguishable
in the absence of haemoglobin
Hp Ba Giblett, Uchida and
Brooks (1966)
An a-chain variant. Designated 1-B and 2-B when the HpaB
allele is combined with Hpa1 or Hpa2 respectively
Hp2-1 Bellevue Javid (1967) A b-chain variant identified by an additional fast moving band
in the b-chain region
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subjects, including those designated Hp0 (Yano et al.,
1998; Beutler, Gelbart & Lee, 2002; Koch et al., 2002;
Carter et al., 2003). Koda et al. (1998) discovered a
congenital cause of anhaptoglobinaemia, designated
HPdel. Sufferers are homozygous or heterozygous for a
deletion that occurs from at least the promoter region
of the HP gene to the 50 flanking region of the b
region of the HPR gene. A PCR has been developed to
determine whether a person has congenital or
acquired anhaptoglobinaemia by testing for the gene
deletion (Koda et al., 2000).
HAPTOGLOBIN CONCENTRATIONS AND
PHENOTYPE
Total concentrations vary with phenotype, being
lower for Hp2-2 subjects than for Hp1-1 and 2-1
(Vanrijn et al., 1987; Langlois & Delanghe, 1996; Kas-
vosve et al., 2000a). Values are lowest for the Hp2-1M
phenotype (found in African populations). Here fewer
Hp2 polypeptides are synthesized than Hp1 polypep-
tides (Maeda, 1991). However, in Chinese subjects,
Hp concentrations were highest for male subjects with
Hp2-2 (Na et al., 2006b).
HAPTOGLOBIN ALLELE FREQUENCIES
WORLDWIDE
In this review, we have collected haptoglobin allele
frequencies from phenotyping surveys and from the
control groups of reports linking haptoglobin to dis-
ease and have tabulated them according to continent
(see Supplementary Material, Tables S1–S5). Rarer Hp
phenotype variants such as Hp2-1M are not tabulated,
and these numbers have been included as the Hp2-1
phenotype. Hp0 data in all surveys refer to subjects
with acquired anhaptoglobinaemia. Hp0 has been
excluded for HP1 and HP2 allele frequency estima-
tions.
The frequencies of HP1 and HP2 in populations
vary worldwide depending upon racial origin but both
have been found in every population examined to
date. There is also a significant difference in the distri-
bution of the HP1F and HP1S alleles in populations
worldwide. Before the development of highly specific
DNA fingerprinting techniques for forensic work, Hp
polymorphisms were used, with other markers, for
the purpose of identification of subjects (Gaensslen,
Bell & Lee, 1987).
AFRICA (F IGURE 2A AND TABLE S1)
In the last few hundred years, Africa has seen an
influx of Caucasian, Mongoloid and Arab popula-
tions. Since the 16th century, Europeans here
migrated to South Africa, while countries in the
north have populations with strong historical, cul-
tural and ethnic ties with the Middle East. There is
a strong Arab influence in North African countries
such as Algeria, whose inhabitants are a mix of Ber-
ber and Arab origin. The Berbers were the original
people of that country until the Arabs arrived in
the seventh century. Arabs now constitute 80% of
the population.
1-12-2 2-1
Cathode
Figure 1. Band distributions of
Hp1-1, Hp2-1 and Hp2-2 using
starch gel electrophoresis.
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AFRICA
0.45 
0.65a
0.28t
Burundi 0.52 
0.57 
0.35b 0.53c Djibouti 0.38 
0.34 
Gambia 
0.51 
0.62
0.57 
0.71
Malawi 
0.56 
0.44 
0.62d
0.24e
0.70
0.69 
0.54g
0.32h
0.54 
Congo  
0.58 
0.40i 
(a)
Igloolik 0.34a
0.30a
0.41b
St Lawrence Is 
0.32a
Caucasian 0.41         ( c ) 
Black 0.55 
Hispanic 0.52 
Asian and oriental 0.31 
0.37b
0.45b
0.59b
0.37 
0.34 
0.48 
(b)
Figure 2. HP1 frequencies
throughout the world. Data are
taken from Roychoudhury and
Nei (1988) supplemented with
later studies (see Supplementary
Material). In general population
samples of <100 have not been
included, except where a num-
ber of populations are combined
for a small area. In almost all
case Hp1-1, 2-1 and 2-2 fre-
quencies were determined by
electrophoresis. The maps were
downloaded from the National
Geographic Society Website
(http://www.nationalgeograph-
ic.com/xpeditions/atlas/). (a)
Africa: aAlgerian Sahara; bCen-
tral Africa Republic, Pygmies;
cSara; dNamibia, Kavango;
eKung San; fBotswana, Bush-
men; gS Africa, Zulu, Xhosa,
Msutu; hBushmen !Kung, Dobe;
IPygmies; Frequencies in grey
boxes are studies where the Hp0
frequency was >20%. (b) North
America: aEskimo; bIndian;
cData from Gaensslen, Bell and
Lee (1987). (c) South America:
These studies are for the Indian
populations of S America only.
(d) Asia: (e) Europe: The mean
frequency of HP1 is 0.386 95%
CI: 0.384–0.388. In total the
European study includes
163 087 subjects. *Significant
difference from the mean fre-
quency for Europe. Note that
frequencies tend to be lower in
Southern and Eastern Europe,
as well as in the far North. (f)
Oceania: aAboriginal popula-
tions; bCombined frequency
from the study of Hill et al.
(1986); c Caucasian population.
Maps are used with permission
of the National Geographic
Society.
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Many tribes remain isolated, either by geography
or by culture. Studies of these tribes should indicate
the true Hp allele frequency for the original Black
inhabitants of the continent. Table S1 shows the
studies performed in Africa. The continent as a
whole has a HP1 allele frequency of 0.56 (95% CI:
0.46–0.66) with up to 47% of people tested being
designated Hp0. However, the individual countries
show marked differences, with surveys in Ghana and
Namibia having HP1 frequencies as low as 0.24
whilst in Nigeria HP1 frequencies were as high as
0.87. The higher HP1 frequencies seem to be linked
to a higher HP1F frequency for those studies with
that data available. Figure 2 illustrates the geography
of the average HP1 and Hp0 frequency for the coun-
tries listed in Table S1.
High Hp0 frequencies are concentrated in the
Western part of the continent. High numbers of Hp0
subjects are attributed to haemolytic diseases and are
found in areas where malaria is endemic. Malaria is
caused by infection of the single cell parasite, Plasmo-
dium, during a bite from the Anopheles mosquito.
Human malaria is most severe when caused by Plas-
modium falciparum, which infects red blood cells and
causes them to rupture in order to release more para-
sites into the blood. When left untreated, this results
Aymar
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All Japan 
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Figure 2. Continued.
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in severe haemolysis and anaemia. The infected sub-
ject is usually left anhaptoglobinaemic, as haptoglobin
complexed with the free haemoglobin released by the
rupture of the cell is rapidly removed from the circu-
lation and is therefore undetectable by conventional
electrophoresis methods. The prevalence of Hp0 is cor-
related with the level of malaria endemicity in several
districts of the Congo (Trape & Fribourgblanc, 1988).
However, both gene promoter polymorphisms (Teye
et al., 2003) and point mutations (Teye et al., 2004)
may also cause the Hp0 phenotype (ahaptoglobinae-
mia) in African populations.
For some countries there are large differences in
the frequencies reported for different surveys. Some
differences may be explained by tribal and cultural
differences in each population surveyed. A good
example of this are the Pygmy populations of the
Congo and the Central African Republic, both of
which show a reduced HP1 allele frequency when
compared with the other surveys of the country
where there has been non-Negroid migration from
other continents. Not all differences are this easily
accounted for. Studies in Namibia and Nigeria show
marked differences in HP1 allele frequency between
ethnically similar populations.
THE AMERICAS (TABLE S2)
Native Indians populated the Americas until the
1500s, when Europeans conquered much of the
0.39 
0.40 
0.40 
0.38
0.40* 
0.41* 
0.40 
0.38 
0.40 
0.40 
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0.34* 
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0.38 
Pyrenees 
0.40 
0.36* 
0.39 
0.35 
0.39
0.37 
0.38 
0.37
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a
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b
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Figure 2. Continued.
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continent. Today, Caucasians dominate the population
of North America and Hispanics South America.
North America (Figure 2b)
Over the last century, North America has become a
truly mixed nation in terms of its ethnic content.
While the majority of the population is Caucasian,
there are also significant numbers of Black, Hispanic
and Oriental subjects who vastly outnumber the ori-
ginal Indian societies. Table S2 shows the HP allele
frequencies for the Americas. The only significant Hp0
frequencies recorded were from surveys of purely
Black people. The surveys of Black communities give
a similar HP1 result (0.55) to that of the continental
average in Africa (0.562), although the Hp0 frequency
is much lower (2.3%). Orientals have a HP1 frequency
of 0.31, higher than the average for SE Asia (0.27),
probably because of inter-racial marriages.
The native Indians and Eskimos can be considered
the closest ethnic groups to the original inhabitants of
this continent. We would expect both of these groups
to be culturally and, in the case of the Eskimos, geo-
graphically isolated. Only the Indian groups show an
increased HP1 allele frequency. The Eskimos have
lower HP1 allele frequencies ranging from 0.24 to
0.32. The Mexican Indians have an average HP1F fre-
quency of 0.38, while the only study to incorporate
HP1F screening for Eskimos detected none (Shim &
Bearn, 1964). Their Hp1-1 frequency was only 3%,
the lowest for the Americas and similar to that seen
in some Asian subcontinents (see later). However,
there were only 67 subjects in the population sample.
South America (Figure 2c)
Indians inhabited the continent of South America
before Spanish conquest. Since then, there has been
an influx of immigrants of Hispanic background. Most
haptoglobin type studies performed in South America
have targeted the native Indians. HP1 frequencies are
high.
ASIA (F IGURE 2D AND TABLE S3)
Asia is the largest of the continents with environmen-
tal extremes ranging from the frozen lands in the
north to the arid deserts in the south. As a rule, those
populations of Caucasian origin are based in the
South and South Western Asia, whilst those in the
East and South East are Mongoloid in origin.
The majority of Asians have very low HP1F values
compared with any other continent, with Indians
averaging about 0.05 and its virtual absence in Japan-
ese, Koreans and Taiwanese. There is also a low but
significant occurrence of the Hp0 type in the South
Eastern part of the continent, which can be related to
the geographical distribution of malaria. For the pur-
pose of this review, we have split the continent into
five subcontinents, listed in alphabetical order as fol-
lows:
East Asia including Japan, Korea, China and Taiwan
HP1 frequencies are approximately 0.3. The highest
HP1 value of 0.387 for Hong Kong may reflect inter-
mixing of genes from other races, although it was a
small sample. The HP1F allele is virtually absent in
East Asia, while HP1S averages 0.273. The frequency
of Hp0 varies from 0% to 3.8%.
Eurasia: Russia, Kazakhstan, Uzbekistan, Ukraine and
Turkey
Although relatively few studies were available for this
subcontinent, there is an interesting pattern emerging
illustrated by a study of Russian populations west of
the Urals (Balanovskaya et al., 2001). HP1 frequencies
tend to increase from northeast (approximately 0.30)
to southwest (approximately 0.46). The HP1 fre-
quency is also high in the Ukraine and in Kazakhstan
where the Russians and the Kazaks have a similar
allele frequency (0.455 and 0.429, respectively)
despite differing racial origins. The subjects studied
from Uzbekistan gave a lower HP1 allele frequency
(approximately 0.27) than their northern neighbours.
One study from Turkey suggests a difference
between the HP1 values of the east and west of the
country. Western Turkey (European) has an HP1
allele frequency of 0.326, whilst Eastern Turkey
(Asian) has 0.200.
South Asia: India, Afghanistan, Nepal
Of the countries in this subcontinent, India is by far
the most studied. The study of 533 subjects in Cal-
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cutta provides the lowest recorded HP1 allele fre-
quency in this review at 0.065 (lower than the overall
value for South Asia of 0.167, P < 0.001). As well as
the low HP1F frequency, approximately 0.05, South
Asians have an HP1S allele frequency of approximately
0.12.
South East Asia: Malaysia, Singapore, Thailand
The countries of this subcontinent are geographically
isolated from one another, but are occupied by ethnic-
ally similar people. HP1 frequencies (approximately
0.294) are similar to those for East Asia (approxi-
mately 0.273). Singapore has a mixture of different
ethnic groups and the study by Saha and Ong (1984)
illustrates the HP1 differences between the majority of
the Singapore population (0.3–0.33) and that of the
Tamil Indians (0.167) who have remained a separate
ethnic group.
South West Asia: Iran, Israel, Jordan, Lebanon, Yemen
This subcontinent shows no significant difference
between each country’s average HP1 allele frequency
and the subcontinental HP1 average of 0.287. How-
ever, Iran is a country with cultural divisions leading
to some significant differences in haptoglobin fre-
quency. The Zoroastrian sect is believed to originate
from the first people of Iran, and ‘outsiders’ are not
accepted into their group – not even other Iranians.
Since the Islamic conquest, Arabs, Turks, Mongols
and Afghans settled in Iran and have contributed to
the other religious sects commonly found in the coun-
try. The Ghashghai are thought to be descended from
the Shah Abbas, who settled in the 1700s from what
is now the USSR. The three distinct groups reported
for Iran show the effect of remaining religiously dis-
tinct (and presumably genetically distinct). The Zoro-
astrian sect have a lower HP1 allele frequency than
was seen in the Moslem or Ghashaghai groups, both
of whom have mixed with other races.
EUROPE (F IGURE 2E AND TABLE S4)
Numerous studies of haptoglobin type frequency have
been reported for Europe. Table S4 summarises stud-
ies with a total of 53 893 subjects. The mean HP1 fre-
quency is 0.381 (95% CI: 0.377–0.385).
The only minor deviations from this come from
Greece and Sardinia and Greenland. The studies of
Greece give an average HP1 frequency of 0.346. This
may be attributed to the lower HP1 allele frequency of
the immigrating people of Western Turkey. Immigra-
tion from North Africa may also explain the higher
than expected average HP1 frequency of 0.43 for Sar-
dinia.
Greenland has a low HP1 value (0.34). The coun-
try’s original HP1 frequency was probably comparable
to its North American neighbours until the more
recent immigration from Denmark, increasing the HP1
allele frequency to what it is today.
There is also an interesting result from a survey in
Norway, which reports a significant decrease in the
HP1 allele frequency of the race of Saamis (0.26),
which is also reflected in a decreased HP1F frequency
(0.065; Teige, Olaisen & Teisberg, 1992). This ethnic
group are one of the aboriginal peoples of the Fennos-
candian area, and are the oldest known Scandinavian
culture, living more or less isolated. The Hp0 fre-
quency was less than 1% in every survey except that
of Allison, Blumberg and ap Rees (1958) who repor-
ted a figure of 2.7% in 218 English subjects.
OCEANIA (F IGURE 2F AND TABLE S5)
This continent is made up of numerous islands that
extend over a vast distance. The HP1 allele frequency
for the continent is 0.571, the highest of all the conti-
nents. Aborigines originally inhabited the largest of
these islands, Australia, until the colonization by
Europeans. Today it holds a mixture of Europeans
(most of the population) with some Orientals in the
more densely populated areas as well as Aboriginals.
This is reflected by two Caucasian surveys that report
a HP1 allele frequency of 0.4. The studies performed
on Australian aborigines show a large range of allele
frequencies (0.18–0.63). Two of the surveys showed a
low frequency of HP1F in the aboriginal people (0–
0.025) compared with the Caucasian study (0.168).
Most of the smaller islands that make up Oceania
are geographically and culturally isolated and there
has been little movement people from other races.
The detailed survey performed in Vanuatu and Papua
New Guinea revealed similar, high HP1 allele frequen-
cies for regions across the island (Hill et al., 1986). The
study provided evidence of anhaptoglobinaemia
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present in the Maewo island of Vanuatu, as well as
finding three cases out of the 165 tested that were Hp
Johnson. In the three countries surveyed by Hill et al.
(1986) HP1F was tested for, but it was not detected.
CONCLUSION
Sutton et al. (1956) made the first comparison of HP
frequencies between populations, when they com-
pared African Blacks and Caucasians. They discovered
a highly significant difference between the two racial
groups, which led to further studies being carried out
on populations worldwide by many authors. These
surveys have found that the frequencies of HP1 and
HP2 vary considerably among people of different racial
origin, but both have always been found in every
population examined to date.
Mongoloids, the Melanesian islanders and most
Australian aborigines are monomorphic for the HP1S
subtype. The HP2 allele is thought to have originated
soon after the divergence of man (Bowman & Kur-
osky, 1982). If so, Mongoloids must have once had
both HP1F and HP1S subtypes, and subsequently lost
HP1F, since HP2 was originally formed during the non-
homologous chromosomal breakage and reunion
between HP1F and HP1S.
The Hp2-1 Modified (Hp2-1M) allele is found
almost exclusively in populations of Black ancestry,
with a frequency ranging from 1% to 10% (Giblett,
1959; Constans et al., 1981; Kasvosve et al., 2002),
although the Hp2-1M allele has also been reported as
1.4% in a Lebanese population (Lefranc et al., 1981).
This can be accounted for, since Lebanese have an
African admixture as demonstrated by the frequency
of Gm haplotypes. Differences in Hp allele frequencies
may be the result of both genetic drift and natural
selection. The functional differences between Hp1-1,
2-1 and 2-2 discussed below provide mechanisms for
selection through protection against particular dis-
eases.
DISEASE ASSOCIATIONS
Changes in total haptoglobin levels in plasma
Hp is an acute phase protein and plasma levels
increase by 200–500% during the 7 days after the
onset of inflammation and only slowly return to nor-
mal during the 2–4 weeks after the removal of the
pathological insult (Gabay & Kushner, 1999).
Levels decrease during haemolysis, ineffective ery-
thropoiesis, liver disease and late pregnancy. Levels
are decreased in people with allergy reactions
(Piessens, Marien & Stevens, 1984). Very low levels
have been reported in familial idiopathic epilepsy
(Panter et al., 1985). The association of Hp2-2 with
protein losing nephropathy may be due to the prefer-
ential loss of the smaller Hp1-1 (Nakhoul et al., 2001).
Haptoglobin types and disease – mechanisms
Free haemoglobin can damage renal tissues and so
any reduction in Hp concentration or Hb binding abil-
ity may result in increased renal damage. Free Hb
may also be a source of iron for pathogenic bacteria,
and reduction in Hp concentration or Hb binding abil-
ity may aggravate bacterial infection (Eaton et al.,
1982). Haptoglobin is an integral part of the acute
phase response – its synthesis being stimulated by IL-
6 (Figure 3). The resulting increase in Hp levels may
also generate a feedback dampening the severity of
the initial acute phase reaction (Arredouani et al.,
2005). Such downregulation may also relate to the
binding of the Hp–Hb complex by macrophage CD163
which leads to secretion of the anti-inflammatory
cytokine IL-10 and the breakdown products of haem
which also have potent anti-inflammatory activity
(Moestrup & Moller, 2004). Release of IL-10 induces
CD163 synthesis and also haem oxygenase-1 via an
autocrine mechanism. Thus there is a co-ordinated
regulation of Hb uptake and breakdown (Philippidis
et al., 2004).
There are differences in the binding of haptoglobin
types by the CD163 receptor. The Hp(2-2)–Hb com-
plex has a 10-fold higher functional affinity for
CD163 than the Hp(1-1)–Hb complex, probably due
to the clustering effect of several binding sites in the
multimeric ligand complex (Graversen, Madsen &
Moestrup, 2002). This may increase the efficiency of
the macrophage in clearing the Hp(2-2)–Hb complexes
from the plasma when compared with that of the
Hp(1-1)–Hb complex binding to CD163 (Graversen,
Madsen & Moestrup, 2002). However, studies in cul-
tured CHO cells transfected with CD163 have demon-
strated more rapid uptake of the Hp(1-1)–Hb complex
than the Hp(2-2)–Hb complex (Asleh et al., 2003).
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Rates of breakdown of Hb within the cell were sim-
ilar. In vitro studies have also demonstrated the pro-
tective effect of Hp against oxidative damage to
erythrocytes by extracellular Hb. Again protection was
greatest for Hp1-1 and least for Hp2-2 (Gueye et al.,
2006).
The difference in size of each haptoglobin pheno-
type may affect both access to tissues and the rate of
clearance of the haptoglobin–haemoglobin complex.
Hp2-2 may provide less protection against haemoglo-
bin iron driven peroxidation leading to lower concen-
trations of ascorbic acid in the plasma of subjects
carrying this Hp type compared with those carrying
Hp1-1 and 2-1(Langlois et al., 1997b; Na et al., 2006a).
Healthy men carrying Hp2-2 had higher levels of
serum iron, serum ferritin and transferrin saturation,
and lower levels of serum transferrin receptor, than
men carrying Hp2-1 and 1-1. L-ferritin concentrations
were also higher in monocytes from Hp2-2 subjects
(Langlois et al., 2000). Van Vlierberghe et al. (2001b))
proposed that Hp2-2 was a potential modifier of iron
status in hereditary haemochromatosis. However, two
later studies showed no correlation between hapto-
globin type and ferritin or transferrin saturation in
C282Y homozygous, hereditary haemochromatosis
patients, asymptomatic, C282Y homozygous blood
donors and random blood donors (Beutler, Gelbart &
Lee, 2002; Carter et al., 2003). Furthermore, Langlois
et al. (2004) did not observe any relationship between
serum ferritin and Hp type in men and women over
50 years old. In men, but not women, Hp2-2 was
associated with increased levels of oxidized low-den-
sity lipoprotein compared with Hp1-1 and Hp2-1. This
association was independent of the increase in oxid-
ized low-density lipoprotein with increasing ferritin
concentration (Brouwers et al., 2004).
Hp2-2 may also be associated with higher serum
total cholesterol levels (Saha et al., 1992; Braeckman
MACROPHAGE
IL-6
CD163
Hp1-1 Hp2-2Free Hb
dimers
+ or
Lysosome
Haem
Carbon monoxide
Fe2+
Biliverdin
Bilirubin
Fn
Fpn1
IL-10
Haem 
oxygenase
Tf-Fe
Signalling? CO
Anti-
inflammatory 
response
+
+
+
Figure 3. Uptake of the Haptoglobin–haemoglobin complex by macrophages. In the plasma Hb tetramers dissociate
into dimers that bind tightly to the b-chain of Haptoglobin. The complex binds to CD163 and is taken up by endo-
cytosis after which both Hp and Hb are degraded in the lysosome. The CD163 receptor is recycled. Haem is degra-
ded to biliverdin and bilirubin. Iron and carbon monoxide are released. Iron is transported to the plasma by
ferroportin-1 or retained within the cell as ferritin. Synthesis of the proteins of the haem degradation pathway is
co-ordinated as IL-6 increases synthesis of Hp, CD163 and haem oxygenease. Binding of the Hp–Hb complex to
CD163 induces intra-cellular signalling leading to increased haem oxygenease activity and release of anti-inflam-
matory cytokines (IL-10). Carbon monoxide release augments the anti-inflammatory response.
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et al., 1999). Neither Borresen et al. (1987) nor Froh-
lander (1987) noted this but Borresen et al. noted a
significantly higher frequency of Hp2-2 among those
with HDL cholesterol values in the upper quartile.
Hp may have a direct regulatory role in the control
of blood flow. Nitric oxide (NO) is a free radical that
plays a principal role in basal blood flow regulation
and vascular homeostasis. As an NO scavenger the
Hp–Hb complex has a role in regulating NO bioavaila-
bility and vascular homeostasis (Wang et al., 2004).
Haptoglobin, by limiting the availability of haem com-
pounds to catalyze the oxidation of arachidonic acid
by prostaglandin synthetase, inhibits prostaglandin
synthesis and so has an anti-inflammatory action
(Jue, Shim & Kamg, 1983).
There is also direct interaction with other cells of
the immune system as Hp suppresses the cytokine
response of T helper cells type 2 (Arredouani et al.,
2003). Hp prevents epidermal LC from spontaneously
undergoing functional maturation in the skin. This
novel property of Hp may be important in amelior-
ating or preventing certain T cell-dependent inflam-
matory skin diseases (Xie et al., 2000). Haptoglobin
binds to monocytes, granulocytes, natural killer cells
and a subset of CD8 T cells through the CD11b/CD18
(MAC1) receptor. Haptoglobin may regulate MAC-1
dependent cell function in vivo. Haptoglobin also
binds to mature B lymphocytes through the CD22
surface receptor (Hanasaki, Powell & Varki, 1995).
Peripheral blood B-cell and CD4+T-lymphocyte counts
are higher in people with Hp2-2 than in 1-1 (Langlois
et al., 1997a). Hp is an angiogenic factor promoting
endothelial cell growth and differentiation of new
blood vessels (Cid et al., 1993; De Kleijn et al., 2002).
Hp2-2 has more angiogenic activity than Hp1-1 or
Hp2-1 (Cid et al., 1993).
Haptoglobin types and disease
Table 3 shows many disease associations linked to
haptoglobin type. Hp1-1 seems to be a susceptibility
factor for infection and liver disease. There are also
negative reports for almost all these associations.
The essential role of Hp in removing free haemo-
globin from the circulation and the existence of sev-
eral Hp types of differing molecular mass suggest the
possibility of associations between Hp types and dis-
ease. Furthermore, the wide differences in frequency
of the Hp types in differing ethnic groups provides the
possibility that particular populations may have a sus-
ceptibility to particular diseases.
Biocore studies indicate that both Hp1-1 and 2-2
bind Hb with similar affinity (Asleh et al., 2005). The
macrophage CD163 receptor has an approximately
eight times greater affinity for Hp2-2 than Hp1-1 yet
studies in cultured CHO cells transfected with CD163
demonstrated more rapid uptake of the Hp(1-1)–Hb
complex (see above). Rates of breakdown of Hb
within the cell were similar. The ability of Hp1-1 to
penetrate intracellular spaces is likely to be greater
than the much larger Hp2-2 molecule. All three fac-
tors indicate that Hp1-1 will be the more effective
molecule in preventing oxidative damage by free Hb.
Normally, there is an excess of Hp compared with free
Hb and differences in the function of Hp types will
not be significant. In the case of diabetes such differ-
ences may be important. Glycosylated Hb is a more
potent source of redox active iron and Hp2-2 has less
ability to inhibit the release of such iron from glycos-
ylated Hb (Asleh et al., 2005). The lack of simple asso-
ciations between Hp type and disease may reflect the
complex interactions between Hp and the immune
system as well as anti-oxidant functions (Figure 3).
CONCLUSION
The population distribution of Hp subtypes through-
out the world and disease associations have been
studied since 1955. The heyday of such studies was in
the 1960s when reports of subtype frequencies in par-
ticular racial groups were published regularly in the
journal Nature. Hp types were used not only to study
the origin of particular populations but also in forensic
science. In both applications, haptoglobin has been
replaced by use of highly polymorphic DNA
sequences. There are remarkable differences in the
frequency of the HP1 allele between racial groups with
frequencies varying from about 0.07 in Calcutta to
over 0.7 in parts of West Africa and South America.
Both HP1 and HP2 have been linked to susceptibility
to various diseases including heart disease and infec-
tion. Such associations may be explained by func-
tional differences between Hp1-1, Hp2-1 and Hp2-2 in
the clearance of haemoglobin from the plasma and in
modulation of immune function. However, there are
many reports drawing the conclusion that there is
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Table 3. Associations between haptoglobin type and disease. These are case control studies with similar or greater
numbers of samples in the control group. Studies with fewer than 50 subjects have not been included. Increased
frequency is indicated by ›, decreased frequency by ﬂ and no change by –
Disease type Specific condition (no. cases)
Hp type or HP1
frequency
Reference1-1 2-1 2-2 HP
1
Cancer Cancer of the ovaries (132) and
non-malignant tumours (114)
– › ﬂ › Dobryszycha and Warwas (1983)
Primary ovarian cancer (175) – – – – Frohlander and Stendahl (1988)
Oesophageal cancer (72) – › – Jayanthi et al. (1989)
Gastric cancer (100) – – › Jayanthi et al. (1989)
Lung cancer (318) – – › ﬂ Bettendorf et al. (1980)
Lung cancer (309) – – – – Beckman et al. (1986)
Bladder cancer (264) – – ﬂ – Benkmann et al. (1987)
Breast cancer (264) – – – – Hudson et al. (1982)
Acute myeloid, lymphoid and
chronic myeloid leukaemia
(multiple studies)
› – – – Nevo and Tatarsky (1986)
Chronic lymphoid leukaemia (140) – – – – Nevo and Tatarsky (1986)
Multiple myeloma (177) – – – – Germenis et al. (1983)
Infection Chronic hepatitis C (239) › – ﬂ Louagie et al. (1996)
Chronic hepatitis C (132) › – – › Van Vlierberghe et al. (2001a)
HIV seropositive Ghanaians (58) Hp0 ﬂ Quaye et al. (2000a)
HIV infected subjects (653) – – – – Delanghe et al. (1998)
HIV infected subjects (387) – – – – Zaccariotto et al. (2006)
Falciparum malaria (273) › ﬂ ﬂ Elagib et al. (1998)
Children with severe
falciparum malaria (113)
› ﬂ ﬂ Quaye et al. (2000b)
Severe malaria (473) – – – – Aucan et al. (2002)
Pulmonary tuberculosis (98) – – – – Kasvosve et al. (2000b)
American trypanasomiasis – – – › Calderoni, Andrade and Grotto (2006)
Liver disease Cirrhosis (107) › ﬂ – › Zhao and Zhang (1993)
Chronic non-alcoholic liver
disease (100)
› – – – Zipprich et al. (1986)
Cirrhosis (174) › – ﬂ › Blenk and Junge (1978)
Diabetes Type II diabetes (265) – – – – Awadallah and Hamad (2000)
Type II diabetes [anglo 97 and
hispanic 191)]
– – – – Iyengar et al. (1989)
Insulin dependent diabetes (144) – – – – Ratzmann et al. (1984)
Type II diabetes in Ghana (129) – – › – Quaye, Ababio and Amoah (2006)
Cardiovascular
disease
Cardiovascular disease (565) – – – – Hong et al. (1997)
Coronary heart disease (200) – – – › Golabi, Kshatriya and Kapoor (1999)
Coronary heart disease
(297 of 3273)
– – – – Levy et al. (2004)
Coronary heart disease
mortality (107)
› – – – De Bacquer et al. (2001)
Peripheral arterial occlusive
disease (141)
– – › ﬂ Delanghe et al. (1999)
Essential arterial hypertension
(302)
– – – – Delanghe et al. (1993)
Essential hypertension (257) – – › Surya Prabha, Padma and
Ramaswamy (1987)
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no association between Hp subtype and a particular
disease.
Clearly many studies are of limited value due to
small sample numbers. Nevertheless, the conflicting
reports of disease associations and the lack of associ-
ation between disease and particular populations
despite the huge range of Hp type proportions across
the world suggests that any associations are marginal.
A true appreciation of the significance of Hp types in
disease awaits a better understanding of the functional
differences between the major Hp types and studies of
large numbers of subjects. So far it is not apparent that
particular populations are at risk from common diseases
because of the prevalence of either HP1 or HP2.
Table 3. Continued
Disease type Specific condition (no. cases)
Hp type or HP1
frequency
Reference1-1 2-1 2-2 HP
1
Cardiovascular
disease
Myocardial infarction (121) – – – – Frohlander and Johnson (1989)
Myocardial infarction (496) – – – – Chapelle et al. (1982)
Preeclampsia (60) › – – – Depypere et al. (2006)
Mental illness
and neurological
disorders
Unipolar major depression (72) › › ﬂ Maes et al. (1994)
Unipolar depression in elderly
patients (65)
– – – – Matsuyama and Joseph (1984)
Schizophrenia (98) ﬂ ﬂ › ﬂ Maes et al. (2001)
Alzheimer disease (several
studies < 100
samples each)
– – – – See Matsuyama, Cripe and
Joseph (1986)
Inflammation Rheumatoid arthritis (200) – – – – Dahlqvist and Frohlander (1985)
and references therein
Family history of polyarthritis
(86)
ﬂ Dahlqvist and Frohlander (1985)
Miscellaneous Haemochromatosis (167) – – › – Van Vlierberghe et al. (2001b)
Haemochromatosis (115) – – – – Beutler, Gelbart and Lee (2002)
Haemochromatosis (173) – – – – Carter et al. (2003)
Sarcoidosis (226) › Fan et al. (1995)
Postmenopausal osteoporosis
(135)
ﬂ – › Pescarmona et al. (2001)
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